NCT05326516已完成1 期
AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed/Refractory Leukemias Harboring Alterations in KMT2A/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 11
- 主要终点
- Number of Participants With Dose Limiting Toxicities From Revumenib
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Days 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have documented relapsed or refractory (R/R) AML, ALL, or acute leukemias of ambiguous lineage (ALAL) including MPAL and acute undifferentiated leukemia (AUL) harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
- •White blood count must be <25,000/microliter prior to the first dose of revumenib. Participants may receive cytoreduction per protocol prior to beginning revumenib.
- •Eastern Cooperative Oncology Group performance status score 0-2 (if aged ≥18 years); Karnofsky Performance Scale of ≥50 (if aged ≥16 years and <18 years); Lansky Performance Score of ≥50 (if aged <16 years).
- •Adequate liver, kidney, and cardiac function
- •Participant must be taking 1 of the following medications for antifungal prophylaxis: itraconazole, ketoconazole, posaconazole, or voriconazole.
- •A female of childbearing potential must agree to use a highly effective method of contraception or double barrier method from the time of enrollment through 120 days following the last study drug dose.
- •A male of childbearing potential must agree to use barrier contraception from the time of enrollment through 120 days following the last study drug dose.
排除标准
- •Any unresolved ≥Grade 2 reversible toxicity from previous anticancer therapy except alopecia or Grade 2 neuropathy
- •Graft-Versus-Host Disease (GVHD): Signs or symptoms of acute or chronic GVHD >Grade 0 within 4 weeks of enrollment. All transplant participants must have discontinued all systemic immunosuppressive therapy for at least 2 weeks and calcineurin inhibitors for at least 4 weeks prior to enrollment. Participants may be on physiological doses of steroids.
- •Concurrent malignancy in the previous 2 years, with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (for example, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy. Concurrent malignancy must be in complete remission or no evidence of disease during this timeframe. For participants with therapy-related leukemia, primary disease must be in remission for 1-year following completion of therapy.
- •If the participant is known to be human immunodeficiency virus (HIV)-positive, the participant must have undetectable HIV viral load within the previous 6 months.
- •Hepatitis B
- •Hepatitis C
- •Cardiac Disease:
- •Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), life-threatening uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack.
- •QTcF interval >450 milliseconds
- •Any gastrointestinal (GI) issue of the upper GI tract that might affect oral drug absorption or ingestion (for example, gastric bypass, gastroparesis).
- •Cirrhosis with a Child-Pugh score of B or C
- •Down Syndrome
- •Genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome.
- •Participation in another therapeutic interventional clinical study within 28 days of starting revumenib.
- •Radiation Therapy: within 60 days from prior total body irradiation, craniospinal radiation and/or ≥50% radiation of the pelvis, or within 14 days from local palliative radiation therapy (small port).
- •Stem Cell Infusion or Donor Lymphocyte Infusion: within 60 days from hematopoietic stem cell transplantation and within 28 days from donor lymphocyte infusion without conditioning.
- •Biologics (for example, monoclonal antibody therapy, bispecific antibodies, and antibody-drug conjugates): within 28 days or 5 half-lives, whichever is longer, since the completion of therapy with a biologic agent.
- •Immunotherapy: within 42 days since tumor vaccines and checkpoint inhibitors, and within 21 days since receipt of chimeric antigen receptor therapy or other modified T-cell therapy.
- •Hematopoietic Growth Factors: within 7 days since the completion of therapy with short-acting hematopoietic growth factors and within 14 days with long-acting growth factors.
研究组 & 干预措施
Revumenib and Chemotherapy Regimen 1
Experimental
Participants with acute lymphoblastic leukemia/mixed phenotype acute leukemia (ALL/MPAL) will receive revumenib every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 1.
干预措施: Revumenib (Drug)
Revumenib and Chemotherapy Regimen 1
Experimental
Participants with acute lymphoblastic leukemia/mixed phenotype acute leukemia (ALL/MPAL) will receive revumenib every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 1.
干预措施: Chemotherapy Regimen 1 (Drug)
Revumenib and Chemotherapy Regimen 2
Experimental
Participants with ALL/MPAL or acute myeloid leukemia (AML) will receive revumenib every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 2.
干预措施: Revumenib (Drug)
Revumenib and Chemotherapy Regimen 2
Experimental
Participants with ALL/MPAL or acute myeloid leukemia (AML) will receive revumenib every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 2.
干预措施: Chemotherapy Regimen 2 (Drug)
结局指标
主要结局
Number of Participants With Dose Limiting Toxicities From Revumenib
时间窗: Day 1 through up to 30 days after last dose of study intervention
Number of Participants With Treatment-emergent Adverse Events
时间窗: Day 1 through up to 30 days after last dose of study intervention
次要结局
- Area Under The Concentration Versus Time Curve From Time 0 To 24 Hours (AUC0-24) Of Revumenib(Predose through up to 6 hours postdose)
- Maximum Plasma Concentration (Cmax) of Revumenib(Predose through up to 6 hours postdose)
- Area Under The Plasma Concentration Versus Time Curve From Time 0 To t (AUC0-t) Of Revumenib(Predose through up to 6 hours postdose)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1VPreventive TherapyPneumonic PlagueNCT00097396DynPort Vaccine Company LLC, A GDIT Company40
已完成
1 期
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)Bladder CancerNCT05375903UroGen Pharma Ltd.51
Unknown
1 期
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid TumorsMedulloblastomaAdenocarcinoma of Esophagogastric JunctionSmall Cell Lung CancerNeuroendocrine NeoplasmBasal Cell CarcinomaGlioblastomaNCT03734913Guangdong Zhongsheng Pharmaceutical Co., Ltd.65
Unknown
1 期
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid TumorsColorectal CancerHepatocellular CarcinomaGastric CancerEsophageal CancerCholangiocarcinomaNCT03734926Guangdong Zhongsheng Pharmaceutical Co., Ltd.90
进行中（未招募）
1 期
AAV Gene Therapy Study for Subjects with PKUPhenylketonuria (PKU)NCT04480567BioMarin Pharmaceutical100